Vcreate
1 known investors
Vcreate uses machine learning and single-cell sequencing screening assays to engineer human T-cell receptors (TCRs) for TCR-based therapies that target disease-specific antigens, including rare cancer mutations. Its platform screens hundreds of millions of TCR-antigen interactions to design receptors that activate against targets inside cells that are otherwise difficult to drug.
Founders & leadership
EF
Ethan FastinCo-Founder and CTO
Investors · 1
Frequently asked questions
- What does Vcreate do?
- Vcreate uses machine learning and single-cell sequencing screening assays to engineer human T-cell receptors (TCRs) for TCR-based therapies that target disease-specific antigens, including rare cancer mutations. Its platform screens hundreds of millions of TCR-antigen interactions to design receptors that activate against targets inside cells that are otherwise difficult to drug.
- Who founded Vcreate?
- Vcreate was founded by Ethan Fast.
- Who are Vcreate's investors?
- Vcreate's investors include Fifty Years.